XML 77 R52.htm IDEA: XBRL DOCUMENT
v3.20.4

Acquisitions and Divestiture (Narrative) (Details) $ / shares in Units, $ in Millions | 1 Months Ended | 3 Months Ended | 11 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | ---
Jan. 31, 2021 USD ($) $ / shares | Feb. 29, 2020 USD ($) | Oct. 31, 2019 USD ($) medicine | Feb. 28, 2019 USD ($) | Mar. 31, 2021 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2020 USD ($) | Dec. 31, 2019 USD ($) | Dec. 31, 2018 USD ($) | Feb. 15, 2019 USD ($)
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  | $ 660.4 | $ 239.6 | $ 1,980.0 |
Goodwill |  |  |  |  |  | $ 3,679.4 | $ 3,679.4 | 3,766.5 | 3,679.4 |  |
Repayments of long-term debt |  |  |  |  |  |  |  | 276.5 | 2,866.4 | 1,009.1 |
Gain related to disposition |  |  |  |  |  |  |  | 0.0 | $ 309.8 | $ 0.0 |
Dermira |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Consideration transferred |  | $ 849.3 |  |  |  |  |  |  |  |  |
Goodwill |  | 86.8 |  |  |  |  |  |  |  |  |
Intangibles acquired |  | 1,200.0 |  |  |  |  |  |  |  |  |
Deferred income tax liabilities assumed |  | 49.5 |  |  |  |  |  |  |  |  |
Long-term debt assumed |  | $ 375.5 |  |  |  |  |  |  |  |  |
Repayments of long-term debt |  |  |  |  |  |  |  | $ 276.2 |  |  |
Loxo Oncology, Inc. |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Consideration transferred |  |  |  | $ 6,920.0 |  |  |  |  |  |  |
Goodwill |  |  |  |  |  |  |  |  |  |  | $ 2,326.9
Deferred income tax liabilities assumed |  |  |  |  |  |  |  |  |  |  | 1,032.8
Acquired IPR&D |  |  |  |  |  |  |  |  |  |  | 4,670.0
Revenue |  |  |  |  |  |  | $ 136.7 |  |  |  |
Loxo Oncology, Inc. | Selpercatinib (LOXO-292) |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D |  |  |  |  |  |  |  |  |  |  | $ 4,600.0
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Legacy Antibiotic Medicines and a Manufacturing Facility in Suzhou, China | Eddingpharm |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of legacy antibiotic medicines rights sold | medicine |  |  | 2 |  |  |  |  |  |  |  |
Proceeds from divestiture of businesses, net of cash divested |  |  | $ 354.8 |  |  |  |  |  |  |  |
Disposal group, not discontinued operation, payment to be received |  |  | $ 40.3 |  |  |  |  |  |  |  |
Gain related to disposition |  |  |  |  |  | $ 309.8 |  |  |  |  |
Subsequent Event | Precision BioSciences, Inc. |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments for acquisitions | $ 100.0 |  |  |  |  |  |  |  |  |  |
Consideration transferred, equity interests purchased | 35.0 |  |  |  |  |  |  |  |  |  |
Subsequent Event | Merus N.V. |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments for acquisitions | 40.0 |  |  |  |  |  |  |  |  |  |
Consideration transferred, equity interests purchased | 20.0 |  |  |  |  |  |  |  |  |  |
Subsequent Event | Forecast | Precision BioSciences, Inc. |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  | $ 107.8 |  |  |  |  |  |
Subsequent Event | Forecast | Merus N.V. |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  | 46.5 |  |  |  |  |  |
Subsequent Event | Prevail Therapeutics Inc. |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments for acquisitions | $ 880.0 |  |  |  |  |  |  |  |  |  |
Business acquisition, share price (in dollars per share) | $ / shares | $ 22.50 |  |  |  |  |  |  |  |  |  |
Contingent value right, additional price per share (in dollars per share) | $ / shares | $ 4.00 |  |  |  |  |  |  |  |  |  |
Contingent value right, additional price per share, aggregate amount | $ 160.0 |  |  |  |  |  |  |  |  |  |
Contingent value right, monthly reduction | $ / shares | $ 0.083 |  |  |  |  |  |  |  |  |  |
Subsequent Event | Asahi Kasei Pharma Corporation | Forecast |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  | $ 20.0 |  |  |  |  |  |

X
- Definition Business Acquisition, Contingent Value Right, Additional Price Per Share + References No definition available. + Details
Name: | lly_BusinessAcquisitionContingentValueRightAdditionalPricePerShare
Namespace Prefix: | lly_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Acquisition, Contingent Value Right, Covenant, Regulatory Approval Occurs + References No definition available. + Details
Name: | lly_BusinessAcquisitionContingentValueRightRegulatoryApprovalDelayMonthlyReduction
Namespace Prefix: | lly_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Acquired In-Process Research And Development + References No definition available. + Details
Name: | lly_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAcquiredInProcessResearchAndDevelopment
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Disposal Group, Not Discontinued Operation, Payment To Be Received + References No definition available. + Details
Name: | lly_DisposalGroupNotDiscontinuedOperationPaymentToBeReceived
Namespace Prefix: | lly_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number Of Medicines, Rights To, Sold + References No definition available. + Details
Name: | lly_NumberOfMedicinesRightsToSold
Namespace Prefix: | lly_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionSharePrice
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(3) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230 + Details
Name: | us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -URI http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b)(1) -URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of cash outflow for purchase of marketable security. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562 + Details
Name: | us-gaap_PaymentsToAcquireMarketableSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the cash inflow during the period from the sale of a component of the entity. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585 + Details
Name: | us-gaap_RepaymentsOfLongTermDebt
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_DermiraInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_LoxoOncologyInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=lly_SelpercatinibLOXO292Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lly_LegacyAntibioticMedicinesAndAManufacturingFacilityInSuzhouChinaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=lly_EddingpharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | lly_AssetAcquisitionAxis=lly_PrecisionBioSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | lly_AssetAcquisitionAxis=lly_MerusNVMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_PrevailTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AsahiKaseiPharmaCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |